drugset / Trial / NCT06462118

A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy Subjects

NCT06462118

Phase 1 Completed 78 enrolled Genentech, Inc.
RandomizedParallel-groupOpen-labelBasic science

Summary

The main objective is to study how astegolimab may behave in the body when injected subcutaneously into the abdomen, thigh, or upper arm in healthy participants.

Timeline

Start
2024-06-17
Primary completion
2024-10-22
Completion
2024-10-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Astegolimab Monoclonal antibody Subcutaneous

Indications

No indication recorded.